Cargando…
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling
BACKGROUND: Tamoxifen (TAM) is widely used in the chemotherapy of breast cancer and as a preventive agent against recurrence after surgery. However, extended TAM administration for breast cancer induces increased VEGF levels in patients, promoting new blood vessel formation and thereby limiting its...
Autores principales: | Kumar, B N Prashanth, Rajput, Shashi, Dey, Kaushik Kumar, Parekh, Aditya, Das, Subhasis, Mazumdar, Abhijit, Mandal, Mahitosh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681557/ https://www.ncbi.nlm.nih.gov/pubmed/23731702 http://dx.doi.org/10.1186/1471-2407-13-273 |
Ejemplares similares
-
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells
por: Sarkar, Siddik, et al.
Publicado: (2013) -
Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer
por: Rajput, Shashi, et al.
Publicado: (2013) -
Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005) -
OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling
por: Song, Feifei, et al.
Publicado: (2019) -
Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)